Identity recordInvestigational clinical program
What Pemvidutide resolves to
This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status.
- Evidence lane
- Clinical pipeline profile
- Current record
- Phase 2 programs active; MASH Phase 3 planned
- Checked
- July 18, 2026
ALT-801balanced GLP-1/glucagon dual agonistAltimmune pemvidutide
Destination recordCategory-dependent
What United States still has to prove
A national guide to separating state-licensed pharmacy access, federal compounding records, approved-drug information, and laboratory-research listings before comparing price.
- Comparison mode
- USD / normalized per mg
- Price coverage
- 78 US listings / 20 boards
- Guide updated
- July 18, 2026